Overview
NewLimit, based in San Francisco, United States, has raised $130M in a Series B round on May 6, 2025, with participation from Kleiner Perkins. The company extending human healthspan. The round will be used to accelerate product development, expand the team, and scale go-to-market operations.
Operating in the biotechnology research sector, NewLimit is positioned to capitalize on growing demand for innovative solutions in this space. The company was founded in 2022 by Blake Byers. Blake brings deep domain expertise and a track record of execution that attracted investor confidence in this round. With fresh capital, the company is expected to invest heavily in R&D and talent acquisition, signaling a period of aggressive growth ahead.
Market Outlook
The successful raise validates NewLimit's approach and market opportunity. Industry analysts note that companies at this funding stage typically grow headcount by 40-60% within 12 months and make significant technology purchasing decisions in the first quarter post-funding. This makes NewLimit's leadership team particularly valuable contacts for B2B outreach in the near term.
Why contact NewLimit now
NewLimit's $130M Series B raise signals serious investor confidence in their biotechnology research play. In the first 90 days post-funding, startups are 3x more likely to respond to outreach and evaluate new partnerships. Their team is hiring, their budget is unlocked, and they need solutions yesterday.
Founders & Contacts
Investors
Company Facts
| Company | NewLimit |
| Amount Raised | $130M |
| Funding Round | Series B |
| Date Raised | May 6, 2025 |
| Founded | 2022 |
| Industry | Biotechnology Research |
| Founders | Blake Byers |
| HQ Location | San Francisco, United States |
Get Verified Founder Emails
Access verified email addresses and contact details for NewLimit's founders and thousands of other funded startups.
Start Free Trial